Chiusura precedente | 161,66 |
Aperto | 161,30 |
Denaro | 160,92 x 1200 |
Lettera | 160,96 x 800 |
Min-Max giorno | 160,25 - 161,40 |
Intervallo di 52 settimane | 150,11 - 181,04 |
Volume | |
Media Volume | 22.720.842 |
Capitalizzazione | 387,473B |
Beta (5 anni mensile) | 0,54 |
Rapporto PE (ttm) | 32,64 |
EPS (ttm) | 4,93 |
Prossima data utili | 17 ott 2023 |
Rendimento e dividendo (futuro) | 4,76 (2,94%) |
Data ex dividendo | 25 ago 2023 |
Stima target 1A | 180,85 |
According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
TORONTO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) has filed and been receipted for a preliminary prospectus by the Canadian securities regulators in connection with the proposed launch of the first yield-focused single-stock ETFs (as outlined below) (collectively, the “ETFs” or “Purpose Yield Shares”). ETF NamesUnderlying Issuer Security Apple (AAPL) Yield SharesApple Inc.Common stockAmazon (AMZ) Yield SharesAmazon.com Inc.Common stockTesla (TSLA) Yield